RE-MODEL Dabigatran Etexilate 150mg or 220mg Once Daily (o.d.) Versus (v.s.) Enoxaparin 40mg o.d. for Prevention of Thrombosis After Knee Surgery

NCT00168805 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

2101

Enrollment

INDUSTRY

Sponsor class

Conditions

Arthroplasty, Replacement, Knee
Thromboembolism

Interventions

DRUG: enoxaparin
DRUG: dabigatran etexilate
DRUG: dabigatran etexilate

Sponsor

Boehringer Ingelheim